This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Area

Beyonttra
®
▼(acoramidis)

Mode of Action

Watch this Short Video discussing the Mode of Action of Beyonttra and how it provides near-complete stabilisation to slow disease progression for your patients with ATTR-CM:

Acoramidis has been specifically designed to mimic the structural influence of the protective T119M mutation

Beyonttra, designed to mimic T119M, provides ≥90% TTR stabilisation in vitro.

The binding capacity of Beyonttra maximises stabilisation of transthyretin and may contribute to reducing amyloid burden, helping preserve heart function and slow disease progression.

Beyonttra TTR

The only stabiliser with near-complete (≥90%) transthyretin (TTR) stabilisation in the label.

Key Messages
Key Messages

* Post-hoc analysis of all-cause mortality and recurrent CV hospitalisations (RRR: 0.58 [95% CI: 0.43-0.79]; p=0.0005) vs placebo at Month 30.

† RRR for frequency of cardiovascular-related hospitalisation per year was 0.496 (95% CI: 0.355-0.695) in favour of acoramidis; p < 0.0001; ARR: 15.9%.

Beyonttra®▼ (acoramidis) - Mechanism of Disease
Learn More about the Mechanism of Disease in ATTR-CM.
PP-BEY-IE-0040-1, November 2025
Beyonttra®▼ (acoramidis) - ATTRibute-CM Study Design
Explore more about the ATTRibute-CM Study Design of evaluating the efficacy & safety of acoramidis vs placebo.
PP-BEY-IE-0036-1, November 2025
Beyonttra®▼ (acoramidis) - CV-related hospitalisation
Explore more about the Efficacy: Cardiovascular-related hospitalisation of Beyonttra® (acoramidis).
PP-BEY-IE-0038-1, November 2025

Abbreviations:

6MWD
, 6-minute walk distance;
ACM
, all-cause mortality;
ARR
, absolute risk reduction;
ATTR-CM
, transthyretin amyloid cardiomyopathy;
CI
, confidence interval;
CFB
, change from baseline;
CVH
, cardiovascular-related hospitalisations;
HR
, hazard ratio;
NT-proBNP
, N-terminal pro-B type natriuretic peptide;
NYHA
, New York Heart Association;
TTR
, transthyretin.
 

 

PP-BEY-IE-0041-1   |   November 2025

 

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professional are asked to report any suspected adverse reactions.